Can MDMA Play a Role in the Treatment of Substance Abuse?

The authors trace MDMA’s therapeutic history from early psychotherapeutic use in the 1970s and 1980s through recent clinical research. Small, early investigations and anecdotal reports described positive changes in attitudes and reduced desire for substances after MDMA-assisted psychotherapy; for example, Greer and Tolbert reported that 14 of 29 participants described decreased desire for alcohol, cannabis or caffeine after at least one MDMA session, though two participants reported increased consumption. More recently, two randomized, blinded, controlled trials found that MDMA-assisted psychotherapy reduced PTSD symptoms in mixed samples of men and women, with effects persisting for at least a year; these PTSD trials excluded people with active substance abuse and did not systematically measure effects on substance use, but neither reported evidence that participants sought out ecstasy afterwards and one study reported negative urinary drug screens during follow-up. Jerome and colleagues discuss pharmacological and subjective mechanisms that could plausibly affect substance use. MDMA is a ring-substituted phenethylamine that releases serotonin, and to a lesser extent norepinephrine and dopamine; it therefore combines serotonergic activity similar to classic psychedelics with stimulant-like catecholaminergic effects comparable to some medications used in addiction treatment. In humans MDMA elevates peripheral oxytocin and produces a distinct subjective state characterised by elevated mood, sociability, empathy and reduced amygdala reactivity. Laboratory studies report enhanced processing of positive facial expressions and reduced detection of negative expressions after MDMA, and neuroimaging shows altered activity in reward- and threat-related regions such as the ventral tegmental area and amygdala. The authors hypothesise that these effects could help in addiction treatment by reducing avoidant coping, increasing self-awareness and empathy, strengthening therapeutic alliance, and by ameliorating comorbid conditions—particularly PTSD—that often perpetuate substance misuse. The review also summarises known risks and uncertainties. MDMA has physiological effects (raised blood pressure and heart rate, modest hyperthermia) and commonly reported acute adverse events in controlled settings include jaw clenching, appetite loss, transient concentration difficulties and short-lived impairments in verbal and visual memory. Serious medical emergencies reported in recreational contexts—hyperthermia, hyponatraemia, liver injury and extreme psychological distress—have not been observed in controlled clinical investigations, where dosing and monitoring differ markedly from party settings. Animal studies using high, repeated doses have shown reductions in brain serotonin and some serotonergic axonal changes, but the authors note dose and pharmacokinetic differences limit direct extrapolation to humans. Human neuroimaging and neurochemical studies are mixed: several investigations reported reduced serotonin transporter availability in regular ecstasy users, while others did not; retrospective studies associate heavy ecstasy use with impaired verbal memory, but a single prospective human study found only a small effect after first exposure. Importantly, trials of MDMA-assisted psychotherapy have typically excluded individuals with current substance-abuse diagnoses (commonly defined as symptoms within 60 days), so the safety and abuse risk of MDMA in people actively using substances is unknown. Given the absence of targeted trials, the investigators conclude that MDMA could conceivably aid people with substance-use disorders either directly via monoaminergic effects on neural reward pathways or indirectly by treating comorbid psychiatric conditions (notably PTSD) and by enhancing therapeutic processes (reduced avoidance, increased empathy and rapport). They contrast MDMA with classic psychedelics, noting psychedelics may carry lower abuse potential and possibly a different risk–benefit profile, while MDMA produces less intense alterations in consciousness and might therefore be better tolerated by some individuals. The authors emphasise that major risks can be mitigated by careful screening for contraindicated medical and psychiatric conditions, but they underscore the critical knowledge gap: no randomised controlled trials have specifically tested MDMA-assisted psychotherapy in people with active substance-abuse disorders. Consequently, they recommend direct empirical studies that include measurement of neurophysiological and neurochemical correlates of response, systematic assessment of changes in substance use, and careful evaluation of risks and benefits in PTSD comorbid with substance abuse.